MyJournals Home  

RSS FeedsPharmaceuticals, Vol. 15, Pages 1485: TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis (Pharmaceuticals)


29 november 2022 07:32:48

Pharmaceuticals, Vol. 15, Pages 1485: TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis (Pharmaceuticals)

Kidney fibrosis is a common pathophysiological mechanism of chronic kidney disease (CKD) progression caused by several underlying kidney diseases. Among various contributors to kidney fibrosis, transforming growth factor-β1 (TGF-β1) is the major factor driving fibrosis. TGF-β1 exerts its profibrotic attributes via the activation of canonical and non-canonical signaling pathways, which induce proliferation and activation of myofibroblasts and subsequent accumulation of extracellular matrix. Over the past few decades, studies have determined the TGF-β1 signaling pathway inhibitors and evaluated whether they could ameliorate the progression of CKD by hindering kidney fibrosis. However, therapeutic strategies that block TGF-β1 signaling have usually demonstrated unsatisfactory results. Herein, we discuss the therapeutic concepts of the TGF-β1 signaling pathway and its inhibitors and review the current state of the art regarding regarding TGF-β1 inhibitors in CKD management.

89 viewsCategory: Medicine, Pharmacology
Pharmaceuticals, Vol. 15, Pages 1484: Next-Generation Heterocyclic Electrophiles as Small-Molecule Covalent MurA Inhibitors (Pharmaceuticals)
Pharmaceuticals, Vol. 15, Pages 1486: Effects of o,p’-DDE, a Mitotane Metabolite, in an Adrenocortical Carcinoma Cell Line (Pharmaceuticals)
blog comments powered by Disqus
The latest issues of all your favorite science journals on one page


Register | Retrieve



Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures News Tweets Nachrichten